TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05883410

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: It is important for the therapist to organize a home exercise program to provide edema and pain control. The exercise program should be specific and clear to the patient. The exercise program will be taught to the patient and given as a home program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: It is important for the therapist to organize a home exercise program to provide edema and pain control. The exercise program should be specific and clear to the patient. The exercise program will be taught to the patient and given as a home program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF Technique
Description: While the limb is in the agonist pattern, the patient is instructed to perform isometric contractions for 5-8 seconds against maximum resistance without movement at the limiting point. After maximum isometric contraction, the patient is instructed to actively relax.Participants in the second group will be applied 10 repetitions of isometric contractions for 8 seconds at the limitation points of the movement with the PNF techniques, the hold and relax active movement technique in the direction of wrist flexion and extension.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mulligan Mobilization
Description: In thw Mobilization with movement technique; the patient is expected to perform painless ROM. After obtaining painless movement in the patients participating in the study, this application will be applied to the patient with the painless active movement technique in 10 repetitions and 2-3 sets. Rest time between sets will be 15-20 seconds. Patients will be taught self-mobilization to ensure the continuity of painless movement. Self-mobilization will be applied by the patient at home with 10 repetitions every two hours (29).
Study: NCT06158269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DVRd
Description: The patients will receive 4 cycles of DVRd induction therapy. After achieving PR or better response, they will receive stem cell mobilization, collection and the following ASCT. Then, the patients will accept 4 cycles of DVRd consolidation and DVR maintenance therapy. Once they sustain MRD negative condition for at least 12 months, the patients will enter the maintenance stage of lenalidomide monotherapy. Otherwise, the triple drug maintenance therapy will be continued for a total of 24 cycles or until disease progression, death, intolerance, withdrawal due to other reasons, or termination/end of the study.
Study: NCT06243211

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DMED
Description: Decompression of spinal cord with stabilization - posterior approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DMED
Description: Decompression of spinal cord with stabilization - posterior approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ANGI
Description: Implantation of nerve tissue following decompression ans stabilization.
Study: NCT04870190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: Almonertinib will be administered orally at a dose of 165 mg per time, Q.D.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Osimertinib will be administered orally at a dose of 80 mg per time, Q.D.
Study: NCT05617703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glass Ionomer with Advanced Glass Hybrid Technology (Equia forte HT fil, GC, Japan)
Description: Advanced Glass Hybrid technology (AGH) was achieved through introduction of ultra-fine highly reactive glass and high-molecular weight polyacrylic acid powders within conventional glass using particles and fillers with close refractive indexes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glass Ionomer with Advanced Glass Hybrid Technology (Equia forte HT fil, GC, Japan)
Description: Advanced Glass Hybrid technology (AGH) was achieved through introduction of ultra-fine highly reactive glass and high-molecular weight polyacrylic acid powders within conventional glass using particles and fillers with close refractive indexes
Study: NCT05151406

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational program
Description: The needed knowledge about hematopoietic stem cell transplantation in a trial to correct their myths and misconceptions about this type of treatment. The educational pamphlet included three theoretical parts: bone marrow transplantation, bone marrow donation, and stem cells banking

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational program
Description: The needed knowledge about hematopoietic stem cell transplantation in a trial to correct their myths and misconceptions about this type of treatment. The educational pamphlet included three theoretical parts: bone marrow transplantation, bone marrow donation, and stem cells banking
Study: NCT06217172

Intervention type: DEVICE
Group type: OTHER
Intervention: RHEUPP App
Description: RHEUPP App; Monthly RAPID3 response; General recommendations for managing Flare through App and Social Monitor for appropriate orientation; 3 month consultation by telehealth.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Follow-up
Description: Usual Care in Rheumatoid Arthritis Ambulatory Service
Study: NCT06080061

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated accelerated radiation therapy
Description: Hypofractionated accelerated radiation therapy
Study: NCT05679648

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonography
Description: studying degree of steatosis

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonography
Description: studying degree of steatosis
Study: NCT06093425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)
Description: All medications administered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)
Description: All medications administered intravenously
Study: NCT06286969

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: The needles are inserted into the subject in a certain way to stimulate specific parts of the body to treat the disease.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: The needles are inserted into the subject in a certain way to stimulate specific parts of the body to treat the disease.
Study: NCT03938922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Investigational Treatment ENT-01
Description: ENT-01 will be administered in tablet form, once daily.~Other Names:~ENT-01
Study: NCT05875818

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: In-clinic Rehabilitation
Description: Effects of In-clinic Rehabilitation for Upper Limb Motor Function in Chronic Stroke Patients

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Tele-rehabilitation
Description: Effects of Tele-rehabilitation for Upper Limb Motor Function in Chronic Stroke Patients
Study: NCT05452447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transfluthrin
Description: Passive emanator with formulated transfluthrin

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Passive emanator with formulated inert ingredients
Study: NCT05733247

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Copenhagen adductor exercise
Description: Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The adduction and abduction partner exercise
Description: Week 1 - 1 session per week consisting of 2 sets of 5 reps of the exercise Week 2 - 2 sessions per week consisting of 2 sets of 6 reps of the exercise Week 3 -3 sessions per week consisting of 3 sets of 6 reps of the exercise Week 4 - 3 sessions per week consisting of 3 sets of 8 reps of the exercise Weeks 5 and 6 - 3 sessions per week consisting of 3 sets of the exercise.
Study: NCT04884893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: 50% nitrous oxide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide
Description: 50% nitrous oxide
Study: NCT05832463

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate blocking supplement (CBS)
Description: The CBS is composed of a Hypromellose outer shell, and filled with mulberry leaf extract, berberine HCl, cinnamon bark powder, and cinnamon bark essential oil.~Mulberry leaf extract (Reducose) - 250 mg Berberine HCl (97%)(Berberis aristata root extract)- 25 mg Organic cinnamon powder (Cinnamon (Cinnamomum loureirii) bark powder) - 20 mg Essential oil blend (Grapefruit (Citrus paradisii) peel oil, Lemon (Citrus limon) peel oil Peppermint (Mentha piperita) aerial (leaf/stem) oil), Ginger (Zingiber officinale) root oil, Cinnamon (Cinnamomum zeylanicum) bark oil) - 5 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: The placebo is composed of a Hypromellose outer shell filled with extra virgin olive oil.
Study: NCT05997056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-sirolimus
Description: Prospective phase 2 single arm, open-label, multi-institutional study to determine the efficacy and safety prospective of nab-sirolimus administered by IV infusion
Study: NCT04765709

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: durvalumab plus platinum-based chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed)
Description: Induction therapy: durvalumab plus histology-based chemotherapy regimen (cisplatin or carboplatin plus vinorelbine for squamous histology and pemetrexed for non-squamous histology).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Durvalumab plus radiotherapy
Description: Concomitant durvalumab and radiotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Consolidation treatment with durvalumab
Study: NCT05608161

Intervention type: DIAGNOSTIC_TEST
Intervention: speech in noise test
Description: The noise masker was a stream of steady-state speech-spectrum noise, whose spectrum was representative of the average spectrum of target sentences. The speech masker was a 47-s loop of digitally combined continuous recordings for Chinese nonsense sentences. Patients from the idiopathic sudden sensorineural hearing loss (ISSNHL) group and control group were tested bilateral (left, right) speech-in-noise (SIN) perception of various signal-to-noise ratios (SNRs) under speech and noise masking conditions. Each participant has to complete four consequent levels of SNRs (-12, -8, -4, 0 decibel (dB) for most of control group, -8, -4, 0, 4 dB for ISSNHL group). In addition, the benefits of spatial separation cues under these two types of masking were analyzed.

Intervention type: DIAGNOSTIC_TEST
Intervention: speech in noise test
Description: The noise masker was a stream of steady-state speech-spectrum noise, whose spectrum was representative of the average spectrum of target sentences. The speech masker was a 47-s loop of digitally combined continuous recordings for Chinese nonsense sentences. Patients from the idiopathic sudden sensorineural hearing loss (ISSNHL) group and control group were tested bilateral (left, right) speech-in-noise (SIN) perception of various signal-to-noise ratios (SNRs) under speech and noise masking conditions. Each participant has to complete four consequent levels of SNRs (-12, -8, -4, 0 decibel (dB) for most of control group, -8, -4, 0, 4 dB for ISSNHL group). In addition, the benefits of spatial separation cues under these two types of masking were analyzed.
Study: NCT06036511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: This is a single arm, open-label, prospective cohort clinical trial.~No blinding is required for this trial.~A total of 14 adult patients with PTSD will be recruited from UNM outpatient clinics and undergo rsfMRI and behavioral assessment prior to ketamine treatment. They will complete baseline scan at day one, a preparatory session (initial part of KAP), IM ketamine treatment, then within 24 hours, an integration session to take advantage of neuroplasticity for optimal therapeutic progress. Each participant will have two complete KAP sessions (preparation, treatment, and integration) followed by rsfMRI within approximately 24 hours, and again approximately two weeks after the completion of the second KAP session. Patients will also have repeat clinical assessments after each treatment. Changes in PTSD symptoms will be correlated with changes in connectivity at each rsfMRI.
Study: NCT05154721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: experimental Group - Mila-Learn
Description: Eight tasks are used in Mila-Learn.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: control Group - Mila-Placebo
Description: Eight tasks similar to Mila-Learn are used in the placebo group
Study: NCT05060627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: In phase 1:~* Dose level -1: Belantamab-Mafodotin 1.9 mg/kg day 1, Q8W~* Dose level 1,2,3: Belantamab-Mafodotin 2.5 mg/kg day 1, Q8W In phase 2: maximum tolerated dose (MTD) of the combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: In phase 1:~* Dose level -1, 1: Carfilzomib 20/45 mg/m2 days 1, 8, and 15, Q4W.~* Dose level 2: Carfilzomib 20/56 mg/m2 on days 1, 8, and 15, Q4W~* Dose level 3: Carfilzomib 20/70 mg/m2 on days 1, 8, and 15, Q4W.~In phase 2: maximum tolerated dose (MTD) of the combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Description: Dexamethasone 40 mg weekly (days 1, 8, 15 and 22) or 20 mg in patients \> 75 years old., Q4W
Study: NCT05911607

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low power laser
Description: Phototherapy for extraction sockets using two different lasers.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low power laser
Description: Phototherapy for extraction sockets using two different lasers.
Study: NCT06242756

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bladder catheterization
Description: Patients placed in the catheterized group will have an indwelling catheter placed after anesthetic has been administered. It would be removed at 12 hours post cesarean section.
Study: NCT06545253

Intervention type: DIAGNOSTIC_TEST
Intervention: microRNAs analysis
Description: Patients will undergo routinary ophthalmological examination, multimodal retinal imaging and blood sampling

Intervention type: DIAGNOSTIC_TEST
Intervention: microRNAs analysis
Description: Patients will undergo routinary ophthalmological examination, multimodal retinal imaging and blood sampling
Study: NCT05130892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: 1 tablet (0.5mg) / time, once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranilast
Description: 1 capsule (0.1g) / time, 3 times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oridonin
Description: 2 tablets (0.5g) / time, 3 times a day;
Study: NCT05404035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Connections for relatives of people with eating disorders and personality disorders
Description: The FC program (Fruzzetti and Hoffman, 2005) is divided into 7 modules:~1. Introduction to the intervention program. Program objectives, guidelines, criteria, and symptoms of ED and PD.~2. Psychoeducation on the development of ED and PD, explanatory theories, available treatments, comorbidity with PD.~3. Emotional regulation skills and awareness, and to decrease emotional reactivity.~4. Skills to improve the quality of relationships in family interactions (letting go of guilt and anger, acceptance skills in relationships).~5. Communication skills and effective self-expression, such as validation.~6. Problem management and making safe plans for crisis management.~7. Making new sense of my relationship with my family member, an opportunity to grow together.~All the modules include practice exercises, video viewing, and homework assignment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Optimized Treatment As Usual
Description: Family members with this condition will continue to receive the usual treatment provided by their referral care center. In addition, we will optimize the treatment, following the recommendations of the international guidelines for the treatment of ED (NICE, 2017). There will be 3 two-hour session in group format each week, with the following components: Up-to-date information and research on ED and PD; Psychoeducation on the development of ED and PD; Explanatory theories; Available treatments and comorbidity.~In both conditions, after each face-to-face session, the participant will be asked to review the contents addressed during the session as homework (independently of the homework corresponding to the specific module being addressed). All interventions carried out with family members will be performed by clinical psychologists or general health psychologists with at least a master's degree or a doctoral degree and previous training in the application of the programs.
Study: NCT05780541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07304814
Description: PF-07304814 is a phosphate ester prodrug of PF-00835231 (active moiety), a potent and selective inhibitor of the SARS-CoV-2 3CLpro.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% sodium chloride solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Antiviral agent

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir
Description: Antiviral agent
Study: NCT05735977

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Indocyanine Green (ICG)
Description: Will the use of ICG delineate the margin between normal kidney parenchyma and renal tumour in children at a macroscopic level and can this be replicated at a microscopic level
Study: NCT05505812

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HS-IT101
Description: Adoptive transfer of 1x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
Study: NCT05606393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality speech training
Description: virtual reality speech training that focuses on receptive and expressive aspects of language, through a newly developed interactive virtual reality software

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional speech therapy
Description: traditional speech therapy in current clinical use, that focuses on language comprehension, naming, fluency, repetition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional speech therapy
Description: traditional speech therapy in current clinical use, that focuses on language comprehension, naming, fluency, repetition.
Study: NCT05539820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Reiki is based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distant Reiki, Reiki practitioners followed the traditional Usui Reiki protocol for distant healing. Reiki practitioners first undertake the name of students and then send the healing energy to the students.
Study: NCT05585996

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T and CD19 CAR-DC
Description: Intravenously injected CAR DC cells and followed by CAR T cells 4 hours later
Study: NCT05337709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education intervention and medication review
Description: Education on osteoarthritis and pain management will be provided to the patients by face-to-face communication at the first meeting, aided with a leaflet, then patients will get the follow-up calls and a video will be shown to enforce the intervention. Medication review includes the assessment of patients' knowledge on the indication, identification of any drug-related problem, and counseling on the proper use of medication.
Study: NCT03564548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPP001
Description: Group assigned to PPP001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine sulfate or Hydromorphone or Oxycodone
Description: Group assigned to morphine sulfate or hydromorphone or oxycodone
Study: NCT05991661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XKH001 Injection
Description: 100mg/ml，1ml/vial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: XKH001 Placebo Injection
Description: 1ml/vial
Study: NCT04786652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: estimated stroke volume variation (esSVV, Nihon Kohden, Japan)
Description: Assessment of the estimated stroke volume variation (esSVV, Nihon Kohden, Japan) in the early postoperative period after OPCAB

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of fluid responsiveness in mechanically ventilated patients after OPCAB
Description: In mechanically ventilated patients after OPCAB within two hrs after intervention: passive leg raising (PLR), increased PEEP, and mini-fluid load (mFL) tests will be followed by standard fluid load (sFL). Monitoring: SVVPCA, PPVPCA, esSVV, HLI, PVI, pre-ejection fraction (PEP, echocardiography), CIPCA, esCI and CISTD. Transthoracic echocardiography will be performed to assess the volume of heart chambers, ejection fraction and pre-ejection phase (PEP).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of fluid responsiveness in spontaneously breathing patients at 18 hrs of the postoperative period
Description: 2) In spontaneously breathing patients at 18 hrs of the postoperative period: PLR, and mFL tests followed by sFL. Monitoring: SVVPCA, PPVPCA, esSVV, PVI, PEP, CIPCA, esCI and CISTD. Transthoracic echocardiography will be performed to assess the volume of heart chambers, ejection fraction and pre-ejection phase.
Study: NCT04856345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking with music with synchronisation
Description: Walking with music than one can synch to

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking with music without synchronisation
Description: Walking with music than one cannot synch to

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: walking without music
Description: Walking without music